DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.

Trial Profile

DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Capecitabine; Docetaxel; Exemestane; Fulvestrant; Letrozole; Paclitaxel; Tamoxifen; Vinorelbine
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms DETECT V/CHEVENDO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Trial design for three trials (DETECT III, DETECT IV and DETECT V) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 28 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top